months, all but one of the survivors had died. We did, however, recognize hypovolemia in some patients in shock with acute myocardial infarction, and these patients could be markedly improved by fluid infusion and avoidance of prolonged pressor infusion. 4 In reviewing the literature from this era, one must recognize that much reported was on the basis of cuff blood pressures, and these pressures could be falsely lower than intravascular pressures by as much as 160 mm Hg.5 In view of this discrepancy, later reports of shock included patients with the clinical shock syndrome and normal intravascular systolic pressure-a group of patients with different therapeutic implications and slightly better prognoses.6 During the same period, investigators changed the definition of successful therapy from the previous criteria of recovery from shock and off pressors for 24 hours to survival of sufficient quality that the patient was able to leave the hospital alive.
During the 1970s, dopamine and dobutamine were developed, and pressure support with inotropic agents could be accomplished more effectively while avoiding the marked vasoconstriction induced by norepinephrine.7 Dobutamine was particularly beneficial for the patient with pump failure but without hypotension because it is a powerful inotropic agent with minimal direct vascular effects. The decrease in ventricular volume so frequently seen with dobutamine allows the inotropic effect to be achieved with little change in myocardial oxygen requirements.8 Vasodilators were used more frequently and earlier in the shock syndrome as accurate monitoring of hemodynamics, particularly arterial pressure, became universally available. This earlier treatment of normotensive or only slightly hypotensive patients with pump failure undoubtedly stopped the progression to hypotensive shock in many patients.9 Intra-aortic balloon counterpulsation was also made available during this decade, and this further allowed these patients to be supported off harsh vasopressors and enabled their transfer to centers where more invasive therapy could be undertaken.101'1 It was also at this time that right ventricular infarction was recognized and treated more effectively. '2 In the experimental animal, it had been shown that very early reperfusion would salvage myocardium. 13 This discovery was applied to treatment of patients with acute myocardial infarction, particularly those who were in hospital at the time of their infarcts, and good results were reported.'415 These patients were not subjected to infarctectomy, just revascularization. They should be separated from another group of patients who developed pump failure, shock, and, frequently, ventricular arrhythmias 7-10 days after the acute myocardial infarction. These patients may have aneurysmal infarct expansion and are treated effectively by infarctectomy with or without revascularization. "l DeWood et al '6 analyzed the most extensive experience in surgical treatment of patients with shock due to acute myocardial infarction and demonstrated improved survival in some patients treated with early revascularization.
Early revascularization with thrombolytic agents has been proposed and is logical. However, it is difficult to demonstrate from the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) Trial or any of the other large trials that, in fact, survival of the shock patient is improved by thrombolysis. This may be a problem of study design in that the GISSI Trial had very little control over subsequent treatment of the patient beyond the use or nonuse of thrombolysis. In many of the Gunnar Cardiogenic Shock and AMI studies done in the United States, the patients with shock were excluded or discouraged from study. Kennedy et al'7 reported improved survival with intracoronary streptokinase, but shock was not well defined in this multicenter experience.
In this issue of Circulation, Lee and coworkers'8 at the University of Michigan present us with data relating remarkable improvement in survival by primary angioplasty in a group of patients in shock from acute myocardial infarction.18 There is no doubt that the angioplasty made a significant difference in survival. It is impossible to do randomized trials in these very sick patients. Therefore, controls have to be historic controls, and the study suffers from all the problems of this methodology. The investigators have tried to match the control patients as well as they can with the treated patients so that age, infarct location, presence of hypertension, or history of previous bypass surgery is not significantly different between the two groups.
It is important to note that more of the patients in the group not offered angioplasty received norepinephrine, whereas more of the patients in the group offered angioplasty were treated with intra-aortic balloon counterpulsation. It is also important to recognize that even though not quite statistically significant, the group not offered angioplasty had longer time from onset of pain to development of shock than did the group offered angioplasty. This could define a group less responsive to reperfusion. On the other hand, it is impressive that the mortality in the group not offered angioplasty was identical with the mortality in the patients who had unsuccessful angioplasty. This is consistent with historic controls, which suggest that the salvage rate for patients treated for acute myocardial infarction and shock seldom exceeds 17% with pharmacological and balloon pump support. It is also consistent with the 19.5% survival reported by Scheidt et al'0 in the large multicenter trial of intra-aortic balloon counterpulsation. The 50% survival rate in the group of patients treated with angioplasty is a marked improvement over all previous reported therapies. There were a small number of patients who had left ventricular filling pressures between 12 The next step in this increasingly aggressive management of pump failure in acute myocardial infarction may include insertion of a mechanical heart, such as the Jarvik, as a bridge to cardiac transplantation. '9 However, this approach is so resource expensive that it cannot be used extensively.
A further implication is that aggressive management of early acute myocardial infarction may prevent the shock syndrome by salvaging myocardium. Patients with hemodynamic instability from acute myocardial infarction should be treated in a facility with expertise immediately available for invasive intervention.
